{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(48)"],"submitter":["Li D"],"pubmed_abstract":["The efficacy of CAR-T cells for solid tumors is unsatisfactory. EpCAM is a biomarker of epithelial tumors, but the clinical feasibility of CAR-T therapy targeting EpCAM is lacking. Here, we report pre- and clinical investigations of EpCAM-CAR-T cells for solid tumors. We demonstrated that EpCAM-CAR-T cells costimulated by Dectin-1 exhibited robust antitumor activity without adverse effects in xenograft mouse models and EpCAM-humanized mice. Notably, in clinical trials for epithelial tumors (NCT02915445), 6 (50%) of the 12 enrolled patients experienced self-remitted grade 1/2 toxicities, 1 patient (8.3%) experienced reversible grade 3 leukopenia, and no higher-grade toxicity reported. Efficacy analysis determined two patients as partial response. Three patients showed >23 months of progression-free survival, among whom one patient experienced 2-year progress-free survival with detectable CAR-T cells 200 days after infusion. These data demonstrate the feasibility and tolerability of EpCAM-CAR-T therapy."],"journal":["Science advances"],"pagination":["eadg9721"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10691766"],"repository":["biostudies-literature"],"pubmed_title":["EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors."],"pmcid":["PMC10691766"],"pubmed_authors":["Yang H","Chen N","Yang J","Jiang L","Li J","Li D","Yang K","Liang X","Guo X","He H","Xu Q","Wei YQ","Zhou W","Su J","Yang Y","Tong A","Huang Y","Hu J","Wang W","Fu M","Shi H"],"additional_accession":[]},"is_claimable":false,"name":"EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors.","description":"The efficacy of CAR-T cells for solid tumors is unsatisfactory. EpCAM is a biomarker of epithelial tumors, but the clinical feasibility of CAR-T therapy targeting EpCAM is lacking. Here, we report pre- and clinical investigations of EpCAM-CAR-T cells for solid tumors. We demonstrated that EpCAM-CAR-T cells costimulated by Dectin-1 exhibited robust antitumor activity without adverse effects in xenograft mouse models and EpCAM-humanized mice. Notably, in clinical trials for epithelial tumors (NCT02915445), 6 (50%) of the 12 enrolled patients experienced self-remitted grade 1/2 toxicities, 1 patient (8.3%) experienced reversible grade 3 leukopenia, and no higher-grade toxicity reported. Efficacy analysis determined two patients as partial response. Three patients showed >23 months of progression-free survival, among whom one patient experienced 2-year progress-free survival with detectable CAR-T cells 200 days after infusion. These data demonstrate the feasibility and tolerability of EpCAM-CAR-T therapy.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-05-28T23:53:29.025Z","creation":"2025-04-04T14:18:43.189Z"},"accession":"S-EPMC10691766","cross_references":{"pubmed":["38039357"],"doi":["10.1126/sciadv.adg9721"]}}